p38α-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3827-3834

  Medicherla, Satyanarayana ^a   Reddy, Mamatha ^a   Jing, Ying Ma ^a   Navas, Tony A ^a   Li, Lingyun ^a   Nguyen, Aaron N ^a   Kerr, Irene ^a   Hanjarappa, Nirupama ^a   Protter, Andrew A ^a   Higgins, Linda S ^a  

^a SCIOS INC   (United States)

Author keywords

Dexamethasone; H 929; HSP 27; MAPK inhibitor; p38; Plasmacytoma; RPMI 8226; SCIO 469; SD 282

Indexed keywords

DEXAMETHASONE; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SCIO 469; SD 282; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; INDOLE 5 CARBOXAMIDE; INDOLE DERIVATIVE; INDOLE-5-CARBOXAMIDE; PROTEIN KINASE INHIBITOR; SCIO-469;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL GROWTH; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; ELECTRIC POTENTIAL; HEAT SHOCK; HISTOLOGY; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OUTCOME ASSESSMENT; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT; ANIMAL; APOPTOSIS; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; DEXAMETHASONE; HUMANS; INDOLES; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 14; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149154965     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J, Hernandez B, Garcia-Frade J, Carrera D, Leon A, Hernandez M, Fernandez AP, Bergua JM, San MJ and Blade J: Prospective pethema study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood, July 8, Epub ahead of print, 2008.
2. Orlowski RZ and Kuhn DJ: Proteosome inhibitor in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1469-1457, 2008.
3. Anderson KC: Lenalidomide and thalidomide: mechanisms of action similarities and differences. Semin Hematol 42: S3-8, 2005.
4. Nishimoto N and Kishimoto T: Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619-626, 2006.
5. Breitkreutz I, Raab MS, Hideshima VS, Raje N, Chauhan D, Munshi C, Richardson PG and Anderson KC: Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haemaol 139: 55-63, 2007.
6. Schindler JF, Monahan JB and Smith WG: p38 Pathway kinases as anti-inflammatory drug targets. J Dent Res 86: 800-811, 2007.
7. Hideshima T, Podar K, Chaushan D, Ishitsuka K, Mitsiades C and Tai YT: p38 MAPK inhibition enhance bortezomib induced cytotoxicity against multiple myeloma cells. Oncogene 23: 8766-8776, 2004.
8. Li M, Cortez S, Nakamachi T, Batuman V and Arimura A: Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res 17: 8796-8803, 2006.
9. Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi Sj, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA and Higgins LS: Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 10: 1909-1923, 2006.
10. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC and Anderson KC: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002.
11. Richardson PG, Barenson J, Irwin D, Jagannath S, Traynor A, Rajkumar V, Alsina M, Kuter D, Srkalovic G, Siegle D, Barlogie B, Alexanian R, Orlowski R, Esseltine D, Kauffman M, Adams J, Schenkein DP and Anderson KC: Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 98: 774-778, 2001.
12. Nozza A, Siracusano L and Armando S: Bortezomib-dexamethasone combination in patient with refractory multiple myeloma and impaired renal function. Clin Ther 28: 953-959, 2006.
13. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL and Anderson KC: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Hematologica 91: 929-934, 2006.
14. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S and Tanaka K: The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246: 243-248, 1998.
15. Tan C and Waldeman TA: Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 62: 1083-1086, 2002.
16. Podar K, Tai Y, Davies F. E, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P and Anderson KC: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98: 428-435, 2001.
17. Dean JL, Brook M, Clark AR and Saklatvala J: p38 Mitogen-activated proteinkinase regulates cyclooxygenase-2 mRNA stability and transcription in lipolysaccharide-treated human monocytes. J Biol Chem 274: 264-269, 1999.
18. Badger AM, Cook MN, Lark MW, Newman-Tarr TM, Swift BA, Nelson AH, Barone FC and Kumar S: SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 161: 467-473, 1998.
19. Stokoe D, Engel K, Campbell DG, Cohen P and Gaestel M: Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat-shock proteins. Febs Lett 313: 307-313, 1992.
20. Vanderkerken K, Medicherla S, Coulton L, Menu E, Protter AA, Higgins LS and Croucher PI: Inhibition of p38 MAPK prevents the development of myeloma bone disease, reduces tumor burden and increases survival in murine models of myeloma. Cancer Res 67: 4572-4577, 2007.
21. Navas TA, Nguyen AN,Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC and Higgins LS: Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20: 1017-1027, 2006.
22. Kyle RA and Rajkumar SV: Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 20:637-664, 2007.
23. Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'Young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI and Higgins LS: Transforming growth factor beta receptor type 1 (TGFbetaR1) kinase activity but not p38 activation is required for TGFbetaR1-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol 20: 518-531, 2006.
24. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK and Prater AA: A selective p38alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen induced arthritis. J Pharmacol Expt Ther 318: 132-141, 2006a.
25. Concannon CG, Gorman AM and Samali A: On the role of HSP27 in regulating apoptosis. Apoptosis 8: 61-70, 2003.